Insider Trading Risk at Life Science Companies: When Boundless Opportunity Meets SEC Scrutiny
Public and private life science companies are a prime target for insider trading schemes and SEC enforcement. While new drugs, therapies, and health applications can have profound impacts on society, information on their efficacy (e.g., FDA approval, clinical trial success) is often non-public, creating countless opportunities for company insiders to reap substantial profits from that information.
The SEC’s recent emphasis on curbing insider trading through increased enforcement and greater disclosure should be top of mind for all life science companies, including privately-held companies, whose material, nonpublic information is still susceptible to being exploited in the securities markets. This webinar will give a primer on insider trading and offer practical guidance on how to protect your company’s material, non-public information, improve your company’s insider trading policies, and prepare for the SEC’s new insider trading disclosures.
CLE Credit: This program is approved for 1.0 CLE credits in CA, NY, & PA; and 1.2 NJ. Uniform Certificates of Attendance will be provided for the purpose of seeking CLE credit in other jurisdictions.
Please register at least two days before the webinar. Login details will be sent to all approved registrants. For more information, contact email@example.com.